| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H7N3O5 |
| Molecular Weight | 225.1583 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)C1=CC=C(O1)\C=N\N2CCOC2=O
InChI
InChIKey=PLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
| Molecular Formula | C8H7N3O5 |
| Molecular Weight | 225.1583 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Furazolidone is a nitrofuran derivarive with broad antibacterial, antiprotazoal properties. It was used for the treatment of bacterial or protozoal enteritis and diarrhea, but now the drug is no longer prescibed in the US. The mechanism of furazolidone action is supposed to be mediated by its binding to bacterial DNA.
Approval Year
Doses
AEs
Sourcing
PubMed
Sample Use Guides
One 100-mg tablet four times daily (adults), 25 to 50 mg four times daily (children).
Route of Administration:
Oral
The in vitro susceptibilities of 50 strains of Salmonella spp., 80 strains of Shigella spp., and 50 enterotoxigenic Escherichia coli, 14 Yersinia enterocolitica, 6 Aeromonas hydrophila, 4 Plesiomonas shigelloides, 9 Vibrio parahaemolyticus, and 30 Campylobacter jejuni strains that were recently isolated from worldwide sources were determined for furazolidone. MICs values were about 0.5-2 ug/ml (Salmonella spp.), 0.5-4 ug/ml (Shigella spp.), 16-128 ug/ml (Y. enterocolitica), 0.5-1 ug/ml (A. hydrophila, V. parahaemolyticus),0.5 ug/ml (P. shigelloides, C. jejuni).
